Intel stock spikes after report of possible US government stake
Warren Eric, the Chief Commercial Officer of Esperion (NASDAQ:ESPR) Therapeutics, Inc. (NASDAQ:ESPR), recently sold a portion of the company's common stock. According to a recent filing, Eric sold 197 shares at a price of $2.165 each, totaling approximately $426. This transaction was conducted on November 19, 2024, and was primarily to satisfy tax obligations on vested shares of restricted stock units. Following this sale, Eric retains 162,355 shares in the company.
In other recent news, Esperion Therapeutics demonstrated robust growth in the third quarter of 2024, primarily driven by the expansion of their product labels. The company reported a 53% year-over-year increase in U.S. net product revenue, amounting to $31.1 million. Total (EPA:TTEF) revenue also saw an uptick, reaching $51.6 million from $34 million in the same quarter last year. Prescription rates have risen by 17%, and international partnerships are flourishing, as evidenced by a 19% increase in royalty revenue.
Esperion has successfully expanded the labels for its products, NEXLETOL and NEXLIZET, and has managed to achieve significant LDL-cholesterol goal achievements with bempedoic acid. The company's financial stability is apparent, with cash and equivalents standing at $144.7 million as of September 2024.
These recent developments indicate Esperion's strong market position and its potential for future growth, as the company continues to focus on U.S. label expansion and strengthening global partnerships. Despite facing gross-to-net headwinds, Esperion remains optimistic about its growth trajectory, as reflected in the company's operating expense guidance of $225 million to $245 million for the full year.
InvestingPro Insights
While Warren Eric's recent sale of Esperion Therapeutics (NASDAQ:ESPR) shares was relatively small and primarily for tax purposes, it's worth examining the company's current financial position and market performance to provide context for investors.
According to InvestingPro data, Esperion's market capitalization stands at $475.84 million, reflecting its position as a small-cap biopharmaceutical company. The company has shown impressive revenue growth, with a 187.12% increase in the last twelve months as of Q3 2024, reaching $295.45 million. This strong growth trajectory aligns with an InvestingPro Tip indicating that analysts anticipate sales growth in the current year.
Despite the revenue growth, Esperion is not yet profitable, as highlighted by another InvestingPro Tip. The company's P/E ratio is negative at -11.75, suggesting that investors are betting on future profitability rather than current earnings. However, it's important to note that Esperion's gross profit margin is healthy at 63.64%, indicating potential for profitability if the company can scale its operations effectively.
Interestingly, Esperion's stock has shown significant momentum recently. The company has delivered a strong return of 35.39% over the last three months and an impressive 97.54% over the past year. This performance is reflected in an InvestingPro Tip highlighting the company's high return over the last year.
For investors seeking more comprehensive analysis, InvestingPro offers additional insights with 11 more tips available for Esperion Therapeutics. These tips could provide valuable guidance on the company's future prospects and potential investment considerations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.